Dr. John M. Joyce, M. D.

Industry-funded research

Named as a principal investigator on 18 industry-funded studies in 2025, from 12 companies. The companies reported $3,894,817 in research payments for these studies, mostly to the institutions running them.

• A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms
  Axsome Therapeutics, Inc.
• A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
  Eli Lilly and Company · Active, not recruiting · NCT06643728
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy
  Vertex Pharmaceuticals Incorporated
• A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are…
  Amgen Inc.
• A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
  Vertex Pharmaceuticals Incorporated
• A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patie…
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
  Eli Lilly and Company · Completed · NCT05882045
• LX9211.1-204-DPN
  Lexicon Pharmaceuticals, Inc.
• A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
  H. Lundbeck A S · Completed · NCT06323928
• An open-label, multicenter trial to assess the safety and tolerability of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder
  Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Psychiatry clinicians in Jacksonville

• Benjamin Adler, DO
• Riaz Ahmed, M.D.
• Sharman S. Allen, M.D.
• Angeles Alvarez-mullin, MD
• Frank N. Anthony, MD
• Mohammad A. Ayubi, M.D.
• Hina Banday, MD
• Colleen E. Bell, MD